Viloxazine ER Maintains Safety, Efficacy for Long-Term Pediatric ADHD Treatment

 ADHD in the News 2023-11-02


Extended-release (ER) viloxazine demonstrates continued safety and efficacy with long-term use for attention-deficit/hyperactivity disorder (ADHD) in children and adolescents, according to results presented at the American Academy of Child and Adolescent Psychiatry (AACAP) 2023 Annual Meeting, held from October 23 to 28, 2023 in New York, New York.

View Article: Psychiatry Advisor, October 31, 2023




Other Articles in this Edition

William Pelham Jr., a groundbreaking researcher in children’s ADHD, dies at 75 in Miami

Youngest children in class with ADHD as likely to keep diagnosis in adulthood as older pupils, find scientists

New genes linked to ADHD identified, potentially paving the way for new treatments

Motor, Behavioral, and Emotional ADHD Symptoms: Methylphenidate or Atomoxetine?

Viloxazine ER Maintains Safety, Efficacy for Long-Term Pediatric ADHD Treatment

Children with ADHD frequently use health care service before diagnosis, study finds

Prenatal complications and familial factors linked to ADHD symptoms in children

Centanafadine Shows Promise in Phase 3 Trials for Adolescent ADHD

New research looks at life satisfaction in pandemic-era teens with mental health histories

Unlicensed Stimulant Doses in Adult ADHD Barely Reduce Symptoms Compared to Licensed Doses

Individuals with ADHD who are evening types are more likely to have depressive symptoms

Surfing the web too much? Study links problematic internet use to heightened ADHD symptoms

Weighted blankets improve sleep in children with ADHD, study shows

How the prolonged ADHD medication shortage is straining patients and their families